HC Wainwright Has Positive Opinion of IOVA FY2026 Earnings

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) – HC Wainwright lifted their FY2026 earnings estimates for Iovance Biotherapeutics in a research report issued to clients and investors on Thursday, November 5th. HC Wainwright analyst J. Pantginis now expects that the biotechnology company will earn ($0.40) per share for the year, up from their previous forecast of ($0.49). HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Iovance Biotherapeutics’ current full-year earnings is ($0.43) per share. HC Wainwright also issued estimates for Iovance Biotherapeutics’ Q4 2026 earnings at ($0.05) EPS and FY2027 earnings at ($0.13) EPS.

A number of other equities research analysts have also recently issued reports on IOVA. Wells Fargo & Company raised their target price on Iovance Biotherapeutics from $14.00 to $18.00 and gave the company an “overweight” rating in a research note on Wednesday, September 30th. Robert W. Baird upped their price target on shares of Iovance Biotherapeutics from $6.00 to $11.00 and gave the stock a “neutral” rating in a research report on Thursday, October 8th. UBS Group increased their price objective on shares of Iovance Biotherapeutics from $7.00 to $8.00 and gave the stock a “neutral” rating in a report on Tuesday, November 3rd. Mizuho lifted their price objective on shares of Iovance Biotherapeutics from $10.00 to $11.00 and gave the company an “outperform” rating in a research report on Tuesday, August 18th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Iovance Biotherapeutics in a research note on Tuesday, September 29th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $13.80.

Iovance Biotherapeutics Price Performance

NASDAQ:IOVA opened at $8.17 on Monday. The firm has a market capitalization of $3.70 billion, a P/E ratio of -15.42 and a beta of 0.88. The business has a 50 day simple moving average of $11.38 and a 200 day simple moving average of $6.00. Iovance Biotherapeutics has a 12-month low of $2.08 and a 12-month high of $15.37.

Iovance Biotherapeutics (NASDAQ:IOVA) last announced its quarterly earnings results on Thursday, November 5th. The biotechnology company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.04. The business had revenue of $121.47 million for the quarter, compared to analysts’ expectations of $115.98 million. Iovance Biotherapeutics had a negative return on equity of 40.51% and a negative net margin of 89.11%. The firm’s revenue was up 64.8% compared to the same quarter last year.

Institutional Investors Weigh In On Iovance Biotherapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Compass Financial Management LLC bought a new position in Iovance Biotherapeutics in the 3rd quarter valued at about $37,000. Valley National Advisers Inc. acquired a new stake in shares of Iovance Biotherapeutics in the 3rd quarter worth approximately $38,000. Root Financial Partners LLC acquired a new stake in shares of Iovance Biotherapeutics in the 3rd quarter worth approximately $44,000. Provenance Wealth Advisors LLC bought a new position in shares of Iovance Biotherapeutics in the third quarter valued at approximately $61,000. Finally, GK Wealth Management LLC bought a new position in shares of Iovance Biotherapeutics in the third quarter valued at approximately $107,000. 77.03% of the stock is currently owned by institutional investors.

About Iovance Biotherapeutics

Iovance Biotherapeutics is a biotechnology company focused on developing and commercializing personalized cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient’s tumor, which are expanded in a laboratory and returned to the patient.

The company’s lead product, Amtagvi (lifileucel), is a TIL therapy approved in the United States for certain adults with unresectable or metastatic melanoma previously treated with specified therapies.